CRA testifies on commercially reasonable efforts and obligations in a novel botanical drug dispute

CRA provided expert reports and trial testimony in a breach of contract litigation involving the development of a novel botanical drug on behalf of the defendant. The plaintiff licensor alleged that the licensee had failed to appropriately develop the product pursuant to its contractual obligations. CRA assessed the licensee’s commercial launch plan and its investments in the development process with respect to the licensee’s “commercially reasonable efforts” obligations and the potential market for the novel product.